A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 47
- Registration Number
- NCT01147484
- Locations
- 🇨🇦
QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦London Regional Cancer Program, London, Ontario, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 8
- Registration Number
- NCT01145989
- Locations
- 🇨🇦
Atlantic Health Sciences Corporation, Saint John, New Brunswick, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦QEII Health Sciences Center, Halifax, Nova Scotia, Canada
Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 19
- Registration Number
- NCT01138384
- Locations
- 🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada
🇨🇦London Regional Cancer Program, London, Ontario, Canada
A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas
- First Posted Date
- 2010-04-28
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 24
- Registration Number
- NCT01112384
- Locations
- 🇨🇦
Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦Ottawa Health Research Institute - General Division, Ottawa, Ontario, Canada
🇨🇦McGill University - Dept. Oncology, Montreal, Quebec, Canada
SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 32
- Registration Number
- NCT01075308
- Locations
- 🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦QEII Health Sciences Center, Halifax, Nova Scotia, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 31
- Registration Number
- NCT01068587
- Locations
- 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦Ottawa Health Research Institute - General Division, Ottawa, Ontario, Canada
🇨🇦Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer
- First Posted Date
- 2009-10-22
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 720
- Registration Number
- NCT01000025
- Locations
- 🇰🇷
Chonnan National University Hwasun Hospital, Jeongnam, Korea, Republic of
🇦🇷CER - Instituto Medico, Buenos Aires, B1878dvb Bs. As., Argentina
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 8
- Registration Number
- NCT00930332
- Locations
- 🇨🇦
Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada
🇨🇦CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 12
- Registration Number
- NCT00869752
- Locations
- 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦Ottawa Health Research Institute - General Division, Ottawa, Ontario, Canada
Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 320
- Registration Number
- NCT00820248
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
🇨🇦BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada